Related Experiment Videos
Collateral methotrexate resistance in cisplatin-selected murine leukemia cells
A Bhushan1, M P Hacker, T R Tritton
1Department of Pharmaceutical Sciences, College of Pharmacy, Idaho State University, Pocatello 83209-8334, USA.
Summary
Researchers found that cancer cells resistant to cisplatin also showed extreme resistance to methotrexate. This resistance is linked to decreased tyrosine phosphorylation of a specific membrane protein, impacting drug uptake and potentially offering new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Anticancer drug resistance is a significant challenge in cancer therapy.
- Mechanisms of drug resistance vary by drug and tumor type.
Purpose of the Study:
- To investigate the mechanism behind collateral resistance to methotrexate in cisplatin-resistant cancer cells.
- To identify the specific molecular alterations responsible for this resistance.
Main Methods:
- Cell line selection for cisplatin resistance.
- Comparative analysis of membrane protein phosphorylation between sensitive and resistant cells.
- Assessment of methotrexate uptake in resistant versus sensitive cells.
Main Results:
- Cisplatin-resistant cells exhibited over 25,000-fold collateral resistance to methotrexate.
- A specific membrane protein (molecular mass = 66) showed decreased tyrosine phosphorylation in resistant cells.
- Reduced phosphorylation correlated with impaired methotrexate transport into the cell.
Conclusions:
- Decreased tyrosine phosphorylation of a membrane protein is a key mechanism for collateral methotrexate resistance.
- This finding offers novel insights into drug resistance.
- Potential for new therapeutic strategies by targeting this protein's phosphorylation status for improved patient survival.